Nkarta, Inc. is a clinical stage biopharmaceutical company pioneering the development of allogeneic off the shelf engineered natural killer (NK) cell therapies. The company focuses on creating therapies that target CD19 positive B cells to treat autoimmune diseases such as lupus nephritis, membranous nephropathy, systemic sclerosis, myositis, and vasculitis. Its lead product candidate NKX019 is a chimeric antigen receptor NK cell therapy designed for off the shelf use. The company’s proprietary NK cell engineering platform uses healthy donor derived NK cells that are expanded and then modified to express a chimeric antigen receptor containing a CD19 binding domain an OX40 costimulatory domain a CD3ζ signaling moiety and membrane bound IL15. This design aims to enhance NK cell recognition of target antigens improve cell persistence and increase antitumor activity while maintaining an off the shelf manufacturing approach.

We have not generated product revenue to date. The company funds its operations through proceeds from public offerings, private placements, and collaboration agreements. All financial resources are directed toward advancing its product candidates through preclinical and clinical development.

Nkarta, Inc. operates in a competitive landscape that includes many companies developing autologous and allogeneic cell therapies, cell engagers and monoclonal antibodies aimed at B cell mediated autoimmune diseases. Competitors developing autologous therapies include AstraZeneca, Autolus, Bristol Myers Squibb, Cabaletta, Cartesian, Gilead, iCell, Juventas, JW Therapeutics, Kyverna, Miltenyi, Novartis, Roche, Rui Therapeutics, and Synthekine. Companies working on allogeneic approaches comprise Adicet, Allogene, Artiva, Atara, CRISPR Therapeutics, Fate Therapeutics, TG Therapeutics, and Sana Biotechnology. Firms pursuing cell engagers are Amgen, Candid, Cullinan, Dragonfly Therapeutics, GlaxoSmithKline, GT Biopharma, Innate Pharma, Merck, Ouro, Roche, Servier, Xencor, and Zenas. Those focusing on monoclonal antibodies are Amgen, Climb Bio, GlaxoSmithKline, Roche, and Zenas. Additionally several firms are investigating in vivo chimeric antigen receptor strategies such as Abbvie, Bristol Myers Squibb, and Lilly. The company’s competitive advantages stem from its off the shelf manufacturing model which may reduce production complexity and cost and from the favorable safety profile observed in early clinical data showing limited cytokine release syndrome and neurotoxicity compared with autologous CAR T cell therapies. The company’s ability to produce large quantities of NK cells from a single donor run supports scalability and cost effectiveness compared with autologous approaches that require individual patient processing.

The company serves patients with autoimmune diseases through its clinical trial programs. As of the filing date NKX019 is being evaluated in two Phase 1 trials for lupus nephritis and membranous nephropathy and for systemic sclerosis myositis and vasculitis. Investigator sponsored trials are also underway for systemic lupus erythematosus and myasthenia gravis. These studies enroll patients with refractory autoimmune disease who have exhausted standard treatment options.